Integra LifeSciences (NASDAQ:IART) Releases FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.400-2.500 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.530-0.610 EPS.

Analysts Set New Price Targets

A number of analysts have weighed in on IART shares. Wells Fargo & Company increased their price target on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. BMO Capital Markets began coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 target price on the stock. Truist Financial raised their target price on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $18.43.

Integra LifeSciences Stock Down 11.0%

Shares of NASDAQ IART traded down $2.16 during trading on Wednesday, hitting $17.60. 773,146 shares of the company traded hands, compared to its average volume of 895,207. The business’s fifty day moving average is $17.61 and its 200 day moving average is $13.41. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -2.73, a P/E/G ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences News Roundup

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Second-quarter earnings exceeded expectations. Integra reported earnings of $0.56 per share, above the $0.48 consensus estimate and up from $0.45 a year earlier. Revenue of $418.76 million was also slightly ahead of the $417.54 million estimate. Integra LifeSciences Q2 Earnings Top Estimates
• Positive Sentiment: Full-year outlook remained consistent with analyst expectations. Integra maintained fiscal 2026 EPS guidance of $2.40-$2.50, compared with the $2.45 consensus, and expects approximately $1.7 billion in revenue. Holding the outlook after the earnings beat provides some support for the company’s operating trajectory. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Third-quarter guidance was broadly in line with forecasts. Integra projected EPS of $0.53-$0.61, compared with the $0.56 consensus, and revenue of $410 million-$425 million versus the $417.3 million estimate. The midpoint of both ranges is close to Wall Street expectations, suggesting limited near-term earnings-estimate upside. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Profitability remains a concern. Despite the per-share earnings beat, Integra reported a negative net margin of 30.15%, which may temper enthusiasm about the quality and sustainability of the earnings improvement.
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $19 price target. The target indicates modest potential upside from recent levels, but the cautious rating may limit buying interest following the earnings release. UBS Initiates Integra LifeSciences Coverage

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after acquiring an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Integra LifeSciences in the first quarter valued at approximately $277,000. Goldman Sachs Group Inc. lifted its stake in Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after purchasing an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Integra LifeSciences in the second quarter worth $491,000. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.